Press Releases
Celleron Therapeutics Successfully Completes Safety Evaluation of Pioneering Combination Therapy Approach to Treating Colorectal Cancer Oxford, UK, 14th January 2019
Read MoreCelleron Therapeutics appoints Simon Cook as its Clinical Research Director Oxford 14 January 2019; Celleron Therapeutics Limited, the UK based
Read MoreOxford 20th December 2018 – Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics,
Read MoreNovember 12th 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today
Read MoreOxford 1st October 2018;Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today
Read More
Oxford 21 September 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced
Read MoreCelleron Therapeutics Begins a Pioneering Combination Therapy Approach to Treating Colorectal Cancer
Oxford, UK, 20th August 2018 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the
Read MoreThe expansion cohort of our Phase I clinical trial is open to patient enrolment.
Read MoreThe company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.
Read MoreUK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.
Read More- « Previous
- 1
- 2
- 3
- 4
- Next »